Cargando…

Anti‐interleukin‐6 antibody clazakizumab in late antibody‐mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism

Targeting interleukin‐6 (IL‐6) is a promising strategy to counteract antibody‐mediated rejection (ABMR). In inflammatory states, IL‐6 antagonism was shown to modulate cytochrome P450 (CYP), but its impact on drug metabolism in ABMR treatment was not addressed so far. We report a sub‐study of a phase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mühlbacher, Jakob, Schörgenhofer, Christian, Doberer, Konstantin, Dürr, Michael, Budde, Klemens, Eskandary, Farsad, Mayer, Katharina A., Schranz, Sabine, Ely, Sarah, Reiter, Birgit, Chong, Edward, Adler, Scott H., Jilma, Bernd, Böhmig, Georg A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456861/ https://www.ncbi.nlm.nih.gov/pubmed/34153143 http://dx.doi.org/10.1111/tri.13954

Ejemplares similares

Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial
por: Eskandary, Farsad, et al.
Publicado: (2019)

Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Kidney Transplant Rejection: Effect on Donor-derived Cell-free DNA and C-X-C Motif Chemokine Ligand 10
por: Mayer, Katharina A., et al.
Publicado: (2022)

Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial
por: Mayer, Katharina A., et al.
Publicado: (2022)

The therapeutic challenge of late antibody‐mediated kidney allograft rejection
por: Böhmig, Georg A., et al.
Publicado: (2019)

Non-invasive Chemokine Detection: Improved Prediction of Antibody-Mediated Rejection in Donor-Specific Antibody-Positive Renal Allograft Recipients
por: Mühlbacher, Jakob, et al.
Publicado: (2020)

Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009—Results from a Randomized First-in-Human Phase 1 Trial
por: Mühlbacher, Jakob, et al.
Publicado: (2017)

Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design
por: Nickerson, Peter W., et al.
Publicado: (2022)

Diagnostic value of donor‐derived cell‐free DNA to predict antibody‐mediated rejection in donor‐specific antibody‐positive renal allograft recipients
por: Mayer, Katharina A., et al.
Publicado: (2021)

Complement Markers in Blood and Urine: No Diagnostic Value in Late Silent Antibody-Mediated Rejection
por: Mező, Blanka, et al.
Publicado: (2019)

Evaluation of Clazakizumab (Anti–Interleukin-6) in Patients With Treatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney Allografts
por: Jordan, Stanley C., et al.
Publicado: (2022)

Longitudinal assessment of HLA and MIC-A antibodies in uneventful pregnancies and pregnancies complicated by preeclampsia or gestational diabetes
por: Küssel, Lorenz, et al.
Publicado: (2017)

Early Estimated Glomerular Filtration Rate Trajectories After Kidney Transplant Biopsy as a Surrogate Endpoint for Graft Survival in Late Antibody-Mediated Rejection
por: Borski, Anita, et al.
Publicado: (2022)

Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial
por: Eskandary, Farsad, et al.
Publicado: (2014)

Torque teno virus for risk stratification of graft rejection and infection in kidney transplant recipients—A prospective observational trial
por: Doberer, Konstantin, et al.
Publicado: (2020)

ABO-Incompatibility: Time to Challenge the Paradigm of Equivalence in Live-Donor Kidney Transplantation?
por: Eskandary, Farsad, et al.
Publicado: (2022)

Treatment of Antibody-Mediated Renal Allograft Rejection: Improving Step by Step
por: Lachmann, Nils, et al.
Publicado: (2017)

Proposed Definitions of Antibody-Mediated Rejection for Use as a Clinical Trial Endpoint in Kidney Transplantation
por: Roufosse, Candice, et al.
Publicado: (2022)

Effect of the Anti‐C1s Humanized Antibody TNT009 and Its Parental Mouse Variant TNT003 on HLA Antibody–Induced Complement Activation—A Preclinical In Vitro Study
por: Wahrmann, M., et al.
Publicado: (2017)

High-activity Classical and Alternative Complement Pathway Genotypes—Association With Donor-specific Antibody-triggered Injury and Renal Allograft Survival
por: Mező, Blanka, et al.
Publicado: (2020)

Relating Molecular T Cell–mediated Rejection Activity in Kidney Transplant Biopsies to Time and to Histologic Tubulitis and Atrophy-fibrosis
por: Madill-Thomsen, Katelynn S., et al.
Publicado: (2023)

Rituximab in Combination With Bortezomib, Plasmapheresis, and High-Dose IVIG to Treat Antibody-Mediated Renal Allograft Rejection
por: Waiser, Johannes, et al.
Publicado: (2016)

Levels of donor‐derived cell‐free DNA and chemokines in BK polyomavirus‐associated nephropathy
por: Mayer, Katharina A., et al.
Publicado: (2022)

Post-Transplant Surveillance and Management of Chronic Active Antibody-Mediated Rejection in Renal Transplant Patients in Europe
por: Rostaing, Lionel P. E., et al.
Publicado: (2023)

Alloimmune Risk Stratification for Kidney Transplant Rejection
por: Bestard, Oriol, et al.
Publicado: (2022)

Multiple drugs: COVID-19 pneumonia and compassionate use of clazakizumab for COVID-19 pneumonia: case report
Publicado: (2020)

Anti-liver kidney microsome antibody recognizes a cytochrome P450 from the IID subfamily
Publicado: (1988)

Quantification of Torque Teno Virus Viremia as a Prospective Biomarker for Infectious Disease in Kidney Allograft Recipients
por: Strassl, Robert, et al.
Publicado: (2018)

MicroRNA regulation in blood cells of renal transplanted patients with interstitial fibrosis/tubular atrophy and antibody-mediated rejection
por: Matz, Mareen, et al.
Publicado: (2018)

Molecular diagnosis of ABMR with or without donor‐specific antibody in kidney transplant biopsies: Differences in timing and intensity but similar mechanisms and outcomes
por: Halloran, Philip F., et al.
Publicado: (2022)

The Cytochrome P450 Homepage
por: Nelson, David R
Publicado: (2009)

Probing the Role of the Hinge Segment of Cytochrome P450 Oxidoreductase in the Interaction with Cytochrome P450
por: Campelo, Diana, et al.
Publicado: (2018)

Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report
por: Vaidya, Gaurang, et al.
Publicado: (2020)

Corticosteroid Treatment Prevents Lipopolysaccharide-Induced Increase of ACE2 and Reduces Fibrin Degradation Products in Bronchoalveolar Lavage Fluid
por: Reindl-Schwaighofer, Roman, et al.
Publicado: (2022)

The FMN “140s Loop” of Cytochrome P450 Reductase Controls Electron Transfer to Cytochrome P450
por: Rwere, Freeborn, et al.
Publicado: (2021)

Donor-Derived Cell-Free DNA in Biopsy-Proven Antibody-Mediated Rejection Versus Recurrent IgA Nephropathy After Kidney Transplantation
por: Akifova, Aylin, et al.
Publicado: (2023)

Dynamic Interaction Between Membrane-Bound Full-Length Cytochrome P450 and Cytochrome b(5) Observed by Solid-State NMR Spectroscopy
por: Yamamoto, Kazutoshi, et al.
Publicado: (2013)

Fungal cytochrome P450 database
por: Park, Jongsun, et al.
Publicado: (2008)

Cytochrome P450 humanised mice
por: Gonzalez, Frank J
Publicado: (2004)

Intronic polymorphisms of cytochromes P450
por: Ingelman-Sundberg, Magnus, et al.
Publicado: (2010)

The Role of Cytochromes P450 in Infection
por: Stavropoulou, Elisavet, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2qv3sehsn35gap6ld1apvfcqo5